The resistance problem
Due to increasing antibiotic resistance and long-term health consequences, H. pylori is categorized as a public health threat by the FDA.1
The American College of Gastroenterology guideline for H. pylori states that...
“Resistance to clarithromycin, metronidazole, and, increasingly, levofloxacin limits the success of common eradication regimens in use today.”2
...as a result, the guideline recommends against using clarithromycin-containing regimens...2
Consequences of not eradicating H. pylori infection
If not eradicated, H. pylori infection can cause chronic progressive gastric inflammation which can lead to3:
- Atrophic gastritis
- Gastric and duodenal ulcers
- Gastric cancer
In fact, approximately 90% of noncardia gastric cancers are H. pylori-related.4
REFERENCES: 1. U.S. Food & Drug Administration. CFR–Code of Federal Regulations Title 21. Section 21CFR317.2. 2. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-239. 3. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
4. Moss S. The clinical evidence linking Helicobacter pylori to gastric cancer. Cell Mol Gastroenterol Hepatol. 2017;3(2):183-191.